Zweig-DiMenna Associates’s Revance Therapeutics, Inc. RVNC Stock Holding History

Zweig-DiMenna Associates’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-83,000	Closed	-$1.41M	–	339
2014 Q4	$1.41M	Sell	83,000 -1,460	-2%	-$25.5K	0.06%	134
2014 Q3	$1.63M	Sell	84,460 -500	-0.6%	-$13K	0.07%	136
2014 Q2	$2.89M	Sell	84,960 -204,646	-71%	-$6.41M	0.13%	119
2014 Q1	$9.12M	Buy	+289,606	New	+$9.05M	0.54%	66

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NHG

NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Zweig-DiMenna Associates's RVNC Position: Q1 2015 in Review

Zweig-DiMenna Associates sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2015, closing a stake of 83,000 shares — an estimated $1.41M sold.

Zweig-DiMenna Associates first reported a position in RVNC in Q1 2014 and held it in 4 quarters. The position peaked at $9.12M in Q1 2014. 70 funds tracked by Wall St. Rank hold RVNC as of Q1 2015.

Zweig-DiMenna Associates reported no remaining Revance Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
Zweig-DiMenna Associates sold 83,000 Revance Therapeutics, Inc. shares in Q1 2015, an estimated $1.41M.
Zweig-DiMenna Associates first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
Zweig-DiMenna Associates's Revance Therapeutics, Inc. position peaked at $9.12M in Q1 2014.
70 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2015.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2015, filed 11 May 2015.